Medtronic's Endeavor DES (drug-eluting stent) gains market approval in China:
This article was originally published in Clinica
Executive Summary
Medtronic has received regulatory approval for its Endeavor drug-eluting stent (DES) from the government of the People's Republic of China. The zotarolimus (ABT-578) delivering stent is built from a cobalt alloy, based on the same platform as the Driver, its bare metal stent product. It is coated with phosphorylcholine, a polymer which mimics the outside surface of a red blood cell, in order improve healing response. The DES market in China currently stands at around $100m, and some 70,000 implants are performed every year, said the Santa Rosa, California-based firm. The firm received CE-marking for the stent in July 2005, and hopes for PMA approval in the US during 2007.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.